Zai Lab Limited logo
Zai Lab Limited ZLAB
$ 18.37 -0.97%

Quarterly report 2025-Q3
added 11-06-2025

report update icon

Zai Lab Limited Financial Ratios 2011-2026 | ZLAB

Annual Financial Ratios Zai Lab Limited

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

P/E

-133.0 -65.2 -86.8 -72.2 -426.1 -17.0 -10.2 -10.7 - - - - - -

P/S

85.7 81.8 178.9 352.5 2340.3 255.8 10956.7 - - - - - - -

EPS

-0.3 -0.3 -0.5 -0.8 -0.3 -3.0 -2.6 -2.3 -4.0 -2.1 - - - -

EV (Enterprise Value)

34.1 B 21.3 B 37.6 B 50.1 B 114 B 3.31 B 1.41 B 325 M 56.5 M 19.1 M - - - -

EBITDA per Share

-0.27 -0.37 -0.41 -0.75 -0.38 -3.1 -2.66 -2.35 - - - - - -

EV/EBITDA

-6.2 -38.3 -16.3 -9.7 -6.1 - - - - - -

PEG

9.18 11.19 73.94 - 3.1 1.15 0.74 0.05 - - - - - -

P/B

40.7 27.4 36.8 36.9 98.0 11.3 5.6 2.3 - - - - - -

P/CF

-159.1 -110.1 -104.7 -92.6 -530.3 -16.1 -13.2 -13.0 - - - - - -

ROE %

-30.57 -42.03 -42.40 -51.05 -23.00 -66.20 -55.39 -21.42 - - - - - -

ROA %

-21.68 -32.29 -36.33 -43.76 -20.72 -54.93 -46.05 -20.18 - - - - - -

ROCE %

-33.55 -46.05 -38.67 -50.73 -25.81 -65.86 -56.00 -21.63 - - - - - -

Current Ratio

3.4 4.3 7.0 7.0 10.1 6.3 5.5 19.1 - - - - - -

DSO

66.0 67.9 74.2 66.6 33.4 106.6 252.9 - - - - - - -

DIO

105.1 145.6 124.7 112.1 208.8 584.6 32.0 - - - - - - -

DPO

265.3 340.9 473.7 659.6 930.2 2206.2 313436.4 - - - - - - -

Operating Cycle

171.1 213.5 198.9 178.7 242.2 691.2 284.9 - - - - - - -

Cash Conversion Cycle

-94.2 -127.4 -274.8 -480.9 -688.0 -1515.0 -313151.5 - - - - - - -

All numbers in USD currency

Quarterly Financial Ratios Zai Lab Limited

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

-0.03 -0.04 -0.04 - -0.04 -0.08 -0.05 - -0.07 -0.13 -0.05 - -0.17 -0.14 -0.09 -2.22 -0.1 -0.18 -0.26 -0.88 -0.84 -1.08 -0.66 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA per Share

-0.04 -0.05 -0.05 - -0.07 -0.08 -0.07 - -0.08 -0.09 -0.07 - -0.13 -0.1 -0.08 -0.23 -0.08 -0.18 -0.26 -1.08 -0.97 -1.1 -0.62 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROE %

-22.09 -23.60 -29.86 -24.66 -32.51 -34.11 -35.68 -25.72 -40.30 -47.03 -45.44 -32.25 -47.60 -39.10 -37.49 -54.26 -45.46 -44.84 -41.96 -23.00 -16.45 -11.00 -4.10 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROA %

-14.96 -16.08 -20.72 -17.77 -24.39 -26.79 -29.59 -21.75 -34.17 -39.95 -38.75 -27.62 -40.78 -33.95 -32.84 -47.94 -40.68 -40.02 -37.61 -20.72 -14.82 -9.91 -3.70 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROCE %

-30.47 -34.20 -38.07 -30.19 -39.68 -39.00 -37.80 -26.03 -37.66 -39.80 -38.34 -25.87 -41.75 -35.37 -37.43 -53.82 -46.08 -47.36 -44.34 -25.81 -17.66 -11.14 -3.96 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Current Ratio

2.9 3.1 3.2 3.4 3.1 3.5 4.4 4.3 6.4 6.4 6.9 7.0 6.7 6.9 7.8 7.0 12.3 8.5 9.3 10.1 10.1 10.1 10.1 5.9 7.2 - - 5.9 - - - 17.3 - - - 14.9 - - - - - - - - - - - - - - - - - - - - - - -

DSO

68.3 68.5 69.3 - 53.4 59.0 62.6 - 58.6 60.0 60.5 - 43.4 57.2 79.0 71.1 41.3 33.2 31.7 31.2 32.2 42.9 49.7 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

DIO

125.7 121.8 110.3 - 101.5 103.5 112.2 - 144.3 143.5 149.7 - 119.4 114.3 114.5 - 88.6 99.7 156.7 - 243.1 414.1 419.2 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

DPO

202.0 223.2 242.0 - 309.4 279.7 272.9 - 218.6 256.1 283.0 - 452.0 541.5 654.3 - 664.1 701.2 632.6 - 1158.5 1973.8 1867.5 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Cycle

194.0 190.2 179.6 - 154.9 162.5 174.8 - 202.9 203.6 210.3 - 162.9 171.6 193.4 71.1 129.9 132.8 188.4 31.2 275.3 457.0 468.9 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cash Conversion Cycle

-8.0 -33.0 -62.4 - -154.5 -117.2 -98.1 - -15.7 -52.5 -72.7 - -289.1 -369.9 -460.9 71.1 -534.2 -568.4 -444.2 31.2 -883.2 -1516.7 -1398.5 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Multiples are an important financial analysis tool for the company Zai Lab Limited, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Adagene Adagene
ADAG
$ 1.65 7.91 % $ 92.9 M chinaChina
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.59 1.99 % $ 8.64 B australiaAustralia
Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals
ARWR
$ 66.05 2.3 % $ 8.83 B usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.52 -16.3 % $ 388 M britainBritain
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Biogen Biogen
BIIB
$ 184.48 -1.67 % $ 26.9 B usaUSA
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
BioNTech SE BioNTech SE
BNTX
$ 102.17 2.32 % $ 27.2 B germanyGermany
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
AstraZeneca PLC AstraZeneca PLC
AZN
$ 93.52 -1.2 % $ 96.9 B britainBritain
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 4.25 1.67 % $ 9.25 B israelIsrael
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Bellicum Pharmaceuticals Bellicum Pharmaceuticals
BLCM
- -9.72 % $ 5.89 M usaUSA
Berkeley Lights Berkeley Lights
BLI
- -7.31 % $ 87 M usaUSA
Bristol-Myers Squibb Company Bristol-Myers Squibb Company
BMY
$ 55.71 -0.28 % $ 113 B usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 207.49 2.22 % $ 5 B danmarkDanmark
Codiak BioSciences Codiak BioSciences
CDAK
- -55.98 % $ 2.15 M usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Cerevel Therapeutics Holdings Cerevel Therapeutics Holdings
CERE
- - $ 7.29 B usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Coherus BioSciences Coherus BioSciences
CHRS
$ 1.61 -5.03 % $ 152 M usaUSA
Catalyst Biosciences Catalyst Biosciences
CBIO
$ 10.84 0.46 % $ 714 M usaUSA
Caladrius Biosciences Caladrius Biosciences
CLBS
- -16.75 % $ 25.8 M usaUSA
Celldex Therapeutics Celldex Therapeutics
CLDX
$ 25.59 -6.54 % $ 1.65 M usaUSA
Cellectis S.A. Cellectis S.A.
CLLS
$ 4.22 -4.2 % $ 116 M franceFrance
Clearside Biomedical Clearside Biomedical
CLSD
- - $ 25.3 M usaUSA
Chimerix Chimerix
CMRX
- - $ 756 M usaUSA
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
- -15.15 % $ 60.3 M britainBritain
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
CORT
$ 37.35 -0.4 % $ 3.86 B usaUSA
Catalyst Pharmaceuticals Catalyst Pharmaceuticals
CPRX
$ 23.18 2.02 % $ 2.75 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Crinetics Pharmaceuticals Crinetics Pharmaceuticals
CRNX
$ 55.11 3.49 % $ 4.45 B usaUSA
CRISPR Therapeutics AG CRISPR Therapeutics AG
CRSP
$ 55.17 2.47 % $ 4.65 B schweizSchweiz
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Zentalis Pharmaceuticals Zentalis Pharmaceuticals
ZNTL
$ 3.53 -5.75 % $ 231 M usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 29.43 6.09 % $ 1.43 B usaUSA